Preliminary Scientific Program - ICTHIC April 8-10, 2016
Friday April 8th 2016
9,00 - 11,00 am
Industry sponsored session
11,00 - 11,15 am
Congress Opening: A Falanga, FR Rickles, B Brenner
11,15 - 1,30 pm
Plenary Session 1: Epidemiology of thrombosis in cancer
Chairs: N Key (USA); TBA
- Venous thromboembolism and occult cancer: impact on clinical practice
M Carrier (Canada)
- Cancer associated thrombosis: risk factors and outcomes
S Eichingher (Austria)
- Update of incidental VTE in cancer
H Liebman (USA)
- Thrombosis and anticancer therapies: the contribution of chemotherapy
and the specific drugs implicated in CAT
P Mismetti (France)
Oral Communications
2,30 - 4,45 pm
Plenary Session 2: Role of hemostatic pathways in cancer progression
Chairs: TBA
- Microparticles and cancer thrombosis in animal models
C Dubois (France)
- Inhibition of platelet function as a target for cancer progression control
J Italiano (USA)
- Biological basis of personalised anticoagulation in cancer: oncomir
networks as regulators of coagulopathy
J Rak (Canada)
- Heparanase procoagulant activity in cancer progression
Y Nadir (Israel)
Oral Communications
5,15 - 7,30 pm
Plenary Session 3: Old and emerging biomarkers for thrombosis and
disease progression in cancer
Chairs: B Brenner (Israel); S Kostantinides (Germany)
- Cancer-associated thrombosis novel biomarker discovery
N Kuderer (USA)
- VTE risk assessment models in cancer
I Pabinger (Austria)
- Polymorphisms of clotting factors and cancer risk
P Sandset (Sweeden)
- The HYPERCAN prospective study
A Falanga (Italy)
Oral Communications
7,30 pm
Plenary Lecture: 4th Simon Karpatkin Memorial Lecture
Chairs: A Falanga (Italy); B Brenner (Israel); FR Rickles (USA)
Introduction to Lecture
FR Rickles (USA)
Targeting clotting proteins in cancer therapy - progress and challenges
W Ruf (USA, Germany)
Saturday April 9th 2016
8,30 - 10,45 am
Plenary Session 4: Hematological malignancies and hemostatic
complications
Chairs: TBA
- Intracranial hemorrhage in cancer patients on anticoagulation
J Zwicker (USA)
- Management of cancer-associated disseminated intravascular
coagulation
M Levi (The Netherlands)
- New insights into the biology and management of thrombosis in
myeloproliferative neoplasms
T Barbui (Italy)
- Update of thrombosis in multiple myeloma
FWG Leebeek (The Netherlands)
Oral Communications
11,15 am - 1,30 pm Plenary Session 5: Risk factors for thrombosis in cancer
Chairs: I Elalamy (France); GM Liumbruno (Italy)
- Upper extremity deep vein thrombosis: comparison between cancer and
non-cancer patients
SM Bleker (The Netherlands)
- Risk of thrombosis and supportive care (transfusion, catheters, growth
factors)
TBA
- New findings from global registries of cancer-associated thrombosis
AK Kakkar (UK)
- Predictors of recurrent VTE and bleeding on anticoagulation
AA Khorana (USA)
Oral Communications
2,30 - 3,00 pm
Special Session: History of ICTHIC
Chair: H Liebman (USA); A Falanga (Italy); B Brenner (Israel)
History of ICTHIC - How has the field progressed since our first meeting in
2001?
F Rickles (USA)
3,00 - 5,00 pm
Poster sessions with refreshments
Poster walk discussion sessions with chair
4,30 - 6,45 pm
Plenary Session 6: Prophylaxis of thrombosis in cancer patients
Chairs: TBA
Thromboprophylaxis in hospitalized Cancer Patients: a comparison of
guidelines
M. Levine (USA)
Long term cardiovascular complications of chemotherapy in patients with
cancer
P. W. Kamphuisen (The Netherlands)
DOACs in cancer patients - what is known and what are the active trials
G Agnelli (Italy)
Oral Communications
Sunday April 10th 2016
8,30 - 10,45 am
Plenary Session 7: Treatment of cancer-associated thrombosis
Chairs: H ten Cate (The Netherlands); G Lyman (USA)
- CAT treatment: guidelines update
AYY Lee (Canada)
- Management of recurrent venous thromboembolism in cancer patients
W Ageno (Italy)
- The use of vena cava filter in patients with cancer
T Wun (USA)
- Management of bleeding complications in cancer patients on DOACs
S Schulman (Canada)
Oral Communications
11,15 am - 1,30 pm Plenary session 8: Open questions in cancer and thrombosis
Chairs: H Buller (Germany)
- Anticoagulant and cancer: Will overall survival increase?
HH Veersteg (The Netherlands)
- Does one size fit all? Who should get LMWH/warfarin/DOACs?
S Noble (UK)
- LMWH in cancer patients with renal impairment - better than warfarin?
R Bauersachs (Germany)
- Laboratory determination of old and new targeted anticoagulant agents
for prevention of bleeding and thrombotic events in cancer patients
J Harenberg (Germany)
Oral Communications
1,30 - 1,45 pm Concluding Remarks